Status:
TERMINATED
A Study of DCC-2701 in Participants With Advanced Solid Tumors
Lead Sponsor:
Deciphera Pharmaceuticals, LLC
Conditions:
Locally Advanced Tumors
Metastatic Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to oth...
Detailed Description
This is a first-in-human study of DCC-2701. The primary purpose of this study is to determine what dose of DCC-2701, can be given safely to patients with advanced solid tumors. The study will have tw...
Eligibility Criteria
Inclusion
- Advanced or metastatic solid tumor that has progressed or was not responsive to standard therapy
- The cancer has no proven effective therapy
- The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)
- Able to swallow tablets
Exclusion
- Have active central nervous system (CNS) metastasis
- Have an active infection of any kind (fungal, viral, or bacterial)
- Are pregnant or breastfeeding
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT02228811
Start Date
June 1 2014
End Date
January 1 2018
Last Update
February 1 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Hospital
Aurora, Colorado, United States, 80045
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
3
The Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
4
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232